Issue link: http://viewer.e-digitaledition.com/i/589857
Sarah Rush, MD, is the Director of Neuro-Oncology and the New Agent and Targeted Therapy Program at Akron Children's. She is shown here with Jeffrey Hord, MD, Director of the Division of Hematology/Oncology. PHOTO © JOE SMITHBERGER, SMITHBERGER PHOTOGRAPHY, NORTH CANTON, OHIO Boardman. The hospital's cancer program is one of only 12 Pediatric Cancer Programs in the country verified by the American College of Surgeons Commission on Cancer. In addition to cancer care, Akron Children's provides comprehensive services such as stem cell and bone marrow trans- plantation to children, teens and young adults with sickle cell disease, hemoglobinopathies and other non-malignant blood disorders. The team has eight pediatric hematologists- oncologists, a psychologist specializing in hematology-oncology, and palliative care providers, certified nurse practitioners, physi- cian assistants and pediatric oncology nurses. Rounding out the team are pharmacists, social workers, clinical research associates, child life specialists, counselors and educa- tors — all devoted to providing long-term medical management, education, counseling, and support for patients and their families. Specialty programs include: + Brain Tumor Clinic + Cancer Survivorship Program + Hemostasis and Thrombosis Center + Infusion Center + Sickle Cell Program + Stem Cell Transplantation Program + Young Women's Bleeding Disorder Clinic Brain Tumor Clinic Sarah Rush, MD, is the director of Neuro- Oncology and the New Agent and Targeted Therapy Program at Akron Children's. A graduate of the University of Cincinnati College of Medicine, Dr. Rush was a resi- dent at Akron Children's before pursuing fellowships in Hematology/Oncology at Vanderbilt University Medical Center and Neuro-Oncology at Children's Hospital Colorado. In 2013, she returned to Akron Children's where her neuro-oncology team sees about 30 new patients a year. "We treat kids with brain and spinal cord tumors," says Dr. Rush. "I'm also respon- sible for the experimental therapeutics portion of our program, and our goal is to improve access to targeted therapies." An important part of that effort relies on a better understanding of the origins of cancer. Akron Children's newly established biobank, a mechanism for collecting tissue and blood samples no longer needed for diagnosis, is critical to the search for new ways to target cancer. "We use the information we collect to explore not only how or why a cancer occurs, but also how to treat it more effectively," says Dr. Rush. "This gives us a platform from which to disseminate our information to the wider oncology community and advance global research efforts." On an individual level, patients benefit when there is a better understanding of the molecular profile of their cancer. Although some pediatric cancers have proven treatments with known toxicities, there are others — certain high-risk tumors, recurrences, or cancers with no standard therapy — where a more personalized approach may be warranted. In these cases, tissue or blood samples can be sent 2 0 1 5 N OV E M B E R / D E C E M B E R ■ M D N E W S . CO M ■ MD NEWS Cleveland/Akron/Canton | 9

